A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Assess The Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The main reason for this study is to see if ART-123 can reduce death in patients who have severe sepsis which results in problems with the way their blood clots and can cause at least one or more of their organs (heart or lungs) to not work properly and in some cases fail.
Description
The purpose of this study is to determine whether ART-123 can reduce mortality when administered to subjects with infection complicated by at least 1 organ dysfunction and coagulopathy.
Details
| Condition | sepsis |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX5388 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.